We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current VYNE market cap is 35.53M. The company's latest EPS is USD -2.0180 and P/E is -1.21.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 167k | 6k | 99k | 135k | 114k |
| Operating Income | -9.33M | -7.98M | -5.88M | -10.32M | -6.23M |
| Net Income | -9.46M | -9.95M | -5.62M | -10.06M | -6.58M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 20.99M | 14.76M | 477k | 424k |
| Operating Income | -76.24M | -198.2M | -68.03M | -34.3M | -29.26M |
| Net Income | -73.7M | -255.83M | -73.33M | -23.21M | -28.45M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 46.91M | 40.76M | 35.26M | 24.96M | 19.27M |
| Total Liabilities | 6.84M | 9.35M | 8.83M | 7.69M | 7.76M |
| Total Equity | 40.07M | 31.2M | 26.43M | 17.27M | 11.51M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 79.17M | 93.74M | 67.05M | 40.76M | 97.69M |
| Total Liabilities | 10.66M | 56.25M | 18.41M | 9.35M | 8.95M |
| Total Equity | 68.51M | 37.49M | 48.64M | 31.2M | 88.74M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.33M | -29.2M | -5.48M | -15.05M | -20.2M |
| Investing | 16.6M | 15.67M | 5M | 5M | 5M |
| Financing | 1.45M | 1.65M | -217k | -222k | -269k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -65.1M | -137.08M | -56.37M | -29.2M | -25.34M |
| Investing | 41.37M | 89.11M | 1.03M | 15.67M | -57.35M |
| Financing | 4.99M | 61.81M | 39.78M | 1.65M | 82.39M |
| Market Cap | 35.53M |
| Price to Earnings Ratio | -1.21 |
| Price to Sales Ratio | 81.4 |
| Price to Cash Ratio | 1.13 |
| Price to Book Ratio | 0.39 |
| Dividend Yield | - |
| Shares Outstanding | 14.1M |
| Average Volume (1 week) | 107.14k |
| Average Volume (1 Month) | 79.8k |
| 52 Week Change | -52.09% |
| 52 Week High | 8.81 |
| 52 Week Low | 1.67 |
| Spread (Intraday) | 0.63 (23.95%) |
| Company Name | VYNE Therapeutics Inc |
| Address |
3411 silverside road tatnall building #104 wilmington, delaware 19810 |
| Website | https://vynetherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
